Genetic medicines such as CAR-T, gene replacement and CRISPR gene editing therapies have achieved transformative clinical outcomes. Despite successes, the high complexity and cost have significantly limited patient access to current ex vivo therapies.

At Tiva Bio, we envision a future where genetic medicines can be precisely and efficiently delivered to targeted cell types in vivo at a fraction of the cost of ex vivo cell and gene therapies.